Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
October 14 2024 - 1:35AM
UK Regulatory
Inventiva announces Filing of 2024 Half-Year Report – Conditions
for Accessing or Consulting the Report
Daix (France), Long Island City (New
York, United States), October 14, 2024 – Inventiva (Euronext
Paris and Nasdaq: IVA) (“Inventiva” or the
“Company”), a clinical-stage biopharmaceutical company
focused on the development of oral small molecule therapies for the
treatment of metabolic dysfunction-associated steatohepatitis
(“MASH”), also known as non-alcoholic steatohepatitis
(“NASH”), and other diseases with significant unmet medical
needs, today announced the filing, for the six-month period ended
June 30, 2024 of its Half-Year Report (the “2024 Half-Year
Report”) with the French financial markets authority,
“Autorité des Marchés Financiers” (“AMF”).
The Company's condensed consolidated interim
financial statements for the six-month period ended June 30, 2024
were prepared under the responsibility of the Board of Directors
and approved by it on a going concern basis on October 14,
2024.
The financial information presented in the 2024
Half Year Report has not been qualified by the statutory auditors
in their reports for the periods concerned. The statutory auditors'
report on the Company's consolidated financial statements for the
year ended December 31, 2023 states that there is a material
uncertainty related to events or circumstances that could affect
the Company's ability to continue as a going concern. The limited
review report on the condensed consolidated financial statements
for the first half of 2024 contains an emphasis of matter paragraph
relating to the going concern assumption.
The 2024 Half-Year Report can be consulted on
the Company's website at www.inventivapharma.com, in the
“Investors” section, and on the AMF website at www.amf-france.org.
Copies of the universal registration document, as amended, are also
available free of charge, on request, from the Company's registered
office at 50 Rue de Dijon, 21121 Daix, France.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH and
other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and
continues to explore other development opportunities to add to its
pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting a candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937 |
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83 |
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
- Inventiva - PR - H1 2024 - EN - 10 14 2024
Inventiva (TG:6IV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Inventiva (TG:6IV)
Historical Stock Chart
From Dec 2023 to Dec 2024